WS
CLSD

Wedbush Securities’s Clearside Biomedical CLSD Stock Holding History

Wedbush Securities’s Portfolio CLSD Stock Details CLSD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,416
Closed -$100K – 1119
2021
Q4 		$100K Buy
+2,416
New +$156K ﹤0.01% 1127
2020
Q4 		– Sell
-1,393
Closed -$32K – 888
2020
Q3 		$32K Sell
1,393
-134
-9% -$3.46K ﹤0.01% 907
2020
Q2 		$43K Hold
1,527
– – ﹤0.01% 917
2020
Q1 		$39K Sell
1,527
-1,186
-44% -$43.9K ﹤0.01% 836
2019
Q4 		$118K Sell
2,713
-1,380
-34% -$29K 0.01% 916
2019
Q3 		$39K Buy
4,093
+26
+0.6% +$373 ﹤0.01% 948
2019
Q2 		$59K Sell
4,067
-33
-0.8% -$589 0.01% 938
2019
Q1 		$85K Sell
4,100
-120
-3% -$2.38K 0.01% 867
2018
Q4 		$68K Sell
4,220
-817
-16% -$38.3K 0.01% 781
2018
Q3 		$465K Buy
+5,037
New +$599K 0.05% 428
2018
Q1 		– Sell
-3,254
Closed -$342K – 833
2017
Q4 		$342K Buy
3,254
+1,300
+67% +$140K 0.04% 501
2017
Q3 		$256K Buy
+1,954
New +$239K 0.03% 615

Other funds holding CLSD

CG
Carmignac Gestion Paris, France $6.51B AUM 19.13% 1-Year Est. Return
ACM
ACT Capital Management Wayne, Pennsylvania $127M AUM
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Wedbush Securities's CLSD Position: Q1 2022 in Review

Wedbush Securities sold out of Clearside Biomedical (CLSD) in Q1 2022, closing a stake of 2,416 shares — an estimated $100K sold.

Wedbush Securities first reported a position in CLSD in Q3 2017 and held it in 12 quarters. The position peaked at $465K in Q3 2018. 60 funds tracked by Wall St. Rank hold CLSD as of Q1 2022.

  • Wedbush Securities reported no remaining Clearside Biomedical position as of Q1 2022 after selling out during the quarter.
  • Wedbush Securities sold 2,416 Clearside Biomedical shares in Q1 2022, an estimated $100K.
  • Wedbush Securities first reported a position in Clearside Biomedical in Q3 2017 and held it in 12 quarters.
  • Wedbush Securities's Clearside Biomedical position peaked at $465K in Q3 2018.
  • 60 funds tracked by Wall St. Rank held Clearside Biomedical as of Q1 2022.

Based on Wedbush Securities's 13F filing for Q1 2022, filed 19 Apr 2022.